Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Charlie Blackie-Kelly | October 29, 2025 | News story | | Pharma&, Rubraca, Scottish Medicines Consortium, nhs scotland, oncology, ovarian cancer
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by the Scottish Medicines Consortium (SMC) as a first-line maintenance therapy for patients in Scotland.
Following the approval, Rubraca is now available as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who have achieved a complete or partial response following completion of first-line platinum-based chemotherapy.
The SMC’s decision was supported by results from the randomised, double-blind, phase 3 ATHENA trial. In the ATHENA-MONO arm of the study, rucaparib was assessed as a monotherapy maintenance treatment in 538 patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The treatment demonstrated statistically significant improvements in progression-free survival (PFS) compared with placebo. The safety profile observed in the study was consistent with both the current US and European licences for rucaparib.
“Today’s acceptance of rucaparib as a first-line maintenance treatment by the Scottish Medicines Consortium marks another step forward in the treatment of advanced ovarian cancer,” said Frank Rotmann, co-founder and managing director, pharma&. “We are dedicated to ensuring that all eligible patients in Scotland can access and potentially benefit from rucaparib.”
Related Content
InnoScot highlights NHS Scotland’s progress towards net zero healthcare
InnoScot Health has highlighted the contribution of NHS Scotland’s sustainability programme to the country’s wider …
Scottish NHS hospital adopts light-activated therapy to reduce surgical infections
NHS Golden Jubilee has become the first hospital in Scotland to introduce a light-activated nasal …
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
